Joseph Jankovic, MD
Financial Relationship: Received an honorarium for this lecture
Nonfinancial Relationship: None
Joseph Jankovic, MD is a professor of Neurology at Baylor College of Medicine where he currently holds the endowed Distinguished Chair in Movement Disorders. He is the founder and director of the Parkinson’s Disease Center and Movement Disorders Clinic, which is recognized as a “Center of Excellence” by the Parkinson’s Foundation. Dr. Jankovic is past president and an honorary member of the International Parkinson’s Disease and Movement Disorder Society. He has been the principal investigator in over one hundred clinical trials and pioneered research on drugs for parkinsonian disorders and hyperkinetic movement disorders that has led to FDA approval. He has published over 1,200 original articles and chapters, and edited or co-edited over 50 books and volumes. He is a recipient of many awards, including the American Academy of Neurology Movement Disorders Research Award. Dr. Jankovic is an active member of many editorial boards and professional organizations, and has served on executive scientific advisory boards, including the Michael J. Fox Foundation for Parkinson’s Research. He is listed in US News & World Report’s “Top Doctors.”
Parkinson’s disease (PD) is one of the most challenging neurodegenerative disorders to treat as it manifests a large variety of troublesome, and often disabling, motor and non-motor symptoms. Despite limitations, such as motor and other complications, levodopa remains the most effective drug in the treatment of PD. This presentation will provide a review of new and emerging forms of medical and surgical therapies. Jankovic will also discuss novel formulations of levodopa, medications that prolong levodopa response and ameliorate levodopa-induced dyskinesias, and innovative delivery methods that are currently being evaluated in clinical trials or are in development with the promise of better efficacy and tolerability. Current strategies designed to slow or delay progression of the disease as potential disease modifying therapies will also be discussed.